Regeneron director exercises options for $3.88M in stock
Alpha Vantage · Benzinga · · AI-summarised by FinFlash
Director Huda Y Zoghbi exercised options on November 5, acquiring 7,439 Regeneron Pharmaceuticals shares worth $3,877,653. The company points to strong revenue growth, high gross margins and prudent debt management, with valuation metrics suggesting potential undervaluation. Analysts carry a $977.93 target versus a $902.90 price, implying 8.3% upside, with ratings at 19 Buy, 8 Hold and 1 Sell.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.